Oryzon Genomics S.A. (ORY.MC)
EUR 1.59
(-3.98%)
EUR 1.59
(-3.98%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -3.35 Million EUR | 20.76% |
| 2022 | -4.23 Million EUR | 9.72% |
| 2021 | -4.68 Million EUR | -37.87% |
| 2020 | -3.39 Million EUR | 0.0% |
| 2019 | - EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 107.17 Thousand EUR | 110.04% |
| 2024 Q3 | -1.37 Million EUR | -1386.72% |
| 2024 Q1 | -1.14 Million USD | 38.02% |
| 2023 Q4 | -1.72 Million EUR | -62.14% |
| 2023 FY | -3.35 Million EUR | 20.76% |
| 2023 Q3 | -1.06 Million EUR | -200.14% |
| 2023 Q2 | 1.06 Million EUR | 165.28% |
| 2023 Q1 | -1.62 Million EUR | 0.0% |
| 2022 Q4 | - EUR | 0.0% |
| 2022 FY | -4.23 Million EUR | 9.72% |
| 2021 FY | -4.68 Million EUR | -37.87% |
| 2020 FY | -3.39 Million EUR | 0.0% |
| 2019 FY | - EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.51 Million EUR | 4.692% |
| ABIVAX Société Anonyme | -147.74 Million EUR | 97.731% |
| Adocia SA | -21.16 Million EUR | 84.156% |
| Aelis Farma SA | -5.07 Million EUR | 33.971% |
| Biophytis S.A. | -17.02 Million EUR | 80.307% |
| Advicenne S.A. | -7.03 Million EUR | 52.312% |
| genOway Société anonyme | 1.56 Million EUR | 313.894% |
| IntegraGen SA | -171.39 Thousand EUR | -1856.221% |
| Medesis Pharma S.A. | -3.95 Million EUR | 15.319% |
| Neovacs S.A. | -8.74 Million EUR | 61.652% |
| NFL Biosciences SA | -3.74 Million EUR | 10.48% |
| Plant Advanced Technologies SA | 79.16 Thousand EUR | 4335.172% |
| Quantum Genomics Société Anonyme | -3.17 Million EUR | -5.739% |
| Sensorion SA | -22.06 Million EUR | 84.803% |
| Theranexus Société Anonyme | -6.82 Million EUR | 50.894% |
| TME Pharma N.V. | -6.73 Million EUR | 50.224% |
| Valbiotis SA | -7.36 Million EUR | 54.493% |
| TheraVet SA | -1.57 Million EUR | -113.467% |
| Valerio Therapeutics Société anonyme | -20.34 Million EUR | 83.519% |
| argenx SE | -272.91 Million EUR | 98.771% |
| BioSenic S.A. | -28.77 Million EUR | 88.349% |
| Celyad Oncology SA | -8.44 Million EUR | 60.311% |
| DBV Technologies S.A. | -67.26 Million EUR | 95.016% |
| Galapagos NV | 211.69 Million EUR | 101.584% |
| Genfit S.A. | -28.89 Million EUR | 88.396% |
| GeNeuro SA | -14.75 Million EUR | 77.279% |
| Hyloris Pharmaceuticals SA | -15.38 Million EUR | 78.199% |
| Innate Pharma S.A. | -7.57 Million EUR | 55.707% |
| Inventiva S.A. | -110.42 Million EUR | 96.964% |
| MaaT Pharma SA | -19.71 Million EUR | 82.995% |
| MedinCell S.A. | -25.03 Million EUR | 86.609% |
| Nanobiotix S.A. | -39.7 Million EUR | 91.554% |
| Onward Medical N.V. | -36.18 Million EUR | 90.733% |
| OSE Immunotherapeutics SA | -23 Million EUR | 85.424% |
| Oxurion NV | -18.96 Million EUR | 82.324% |
| Pharming Group N.V. | -9.75 Million EUR | 65.634% |
| Poxel S.A. | -35.09 Million EUR | 90.445% |
| GenSight Biologics S.A. | -26.22 Million EUR | 87.212% |
| Transgene SA | -22.32 Million EUR | 84.983% |
| Financière de Tubize SA | 88.15 Million EUR | 103.804% |
| UCB SA | 343 Million EUR | 100.978% |
| Valneva SE | -101.42 Million EUR | 96.694% |
| Vivoryon Therapeutics N.V. | -28.34 Million EUR | 88.17% |